Celularity (NASDAQ:CELU – Get Free Report) and Abivax (NASDAQ:ABVX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Institutional & Insider Ownership
19.0% of Celularity shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings for Celularity and Abivax, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celularity | 1 | 0 | 1 | 0 | 2.00 |
| Abivax | 1 | 2 | 12 | 0 | 2.73 |
Earnings & Valuation
This table compares Celularity and Abivax”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celularity | $26.55 million | 0.78 | -$91.72 million | ($3.33) | -0.21 |
| Abivax | N/A | N/A | -$380.27 million | ($5.21) | -18.53 |
Celularity has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Celularity has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Profitability
This table compares Celularity and Abivax’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celularity | -345.45% | N/A | -77.94% |
| Abivax | N/A | -99.02% | -70.26% |
Summary
Celularity beats Abivax on 7 of the 13 factors compared between the two stocks.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
About Abivax
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
